This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GlaxoSmithKline responds to letter from Senator Grassley

Philadelphia, PA - January 30, 2008 

On May 3, 2007, a peer reviewer contacted GlaxoSmithKline (GSK) about an article related to Avandia® (rosiglitazone maleate)that he had been asked to review by the New England Journal of Medicine. The reviewer told GlaxoSmithKline he had concerns and questions regarding the methodology of the analysis, and sent the article to GlaxoSmithKline for advice from experienced statisticians. GlaxoSmithKline did not provide comments or any other input on the manuscript to the reviewer.  We believe GlaxoSmithKline acted appropriately and responsibly in responding to the situation.

Inquiries

US Media inquiries:	Nancy Pekarek	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
UK Media inquiries:	Phil Thomson	(020) 8047 5502
	Alice Hunt	(020) 8047 5502
	Joss Mathieson	(020) 8047 5502
	Claire Brough	(020) 8047 5502
US Analyst/ Investor inquiries:	Frank Murdolo	(215) 751 7002
	Tom Curry	(215) 751 5419
European Analyst/Investor inquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543